



Genomic Alterations in Leukemia (Volume II)

Guest Editor:

Dr. Ilaria Iacobucci

Department of Pathology, St.
Jude Children's Research
Hospital, Memphis, TN 38105,
USA

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,

Acute leukemias, specifically acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), are influenced by genetic alterations that have significant clinical, prognostic, and therapeutic implications. Detecting these alterations and their associated transcriptional signatures is essential for diagnosis, risk assessment, and treatment. The complexity of leukemic cells, along with the expansion of resistant clones, can contribute to disease persistence or recurrence. Single-cell technologies have provided insights into clonal heterogeneity, cell developmental state composition, and interactions with the microenvironment, advancing our understanding of acute leukemia pathogenesis and treatment response.

This Special Issue will showcase the latest advancements in ALL and AML research, including genetic discoveries, faithful cellular and in vivo models, and computational analysis methods. It aims to improve the analysis of acute leukemia at both bulk and single-cell resolution, enhance clinical management, and refine therapeutic approaches.

Dr. Ilaria Iacobucci
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)